Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

NSMB’s 30th anniversary

Chemical rewiring of ubiquitination by degraders and their selectivity routes

This article has been updated

Ubiquitination is an essential process that curtails cellular levels of damaged and redundant proteins. Chemical biologists have harnessed this natural system to induce the degradation of disease-relevant proteins. We reflect here on the potential of ‘degraders’ for targeted selectivity, and discuss the role of computer-aided drug design in shaping future advances.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The main modalities and advantages of targeted protein degradation.

Change history

  • 04 March 2024

    In the version of the article initially published, an earlier, incorrect version of Fig. 1 was included. This has now been amended in the HTML and PDF versions of the article.

References

  1. Békés, M., Langley, D. R. & Crews, C. M. Nat. Rev. Drug Discov. 21, 181–200 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Domostegui, A., Nieto-Barrado, L., Perez-Lopez, C. & Mayor-Ruiz, C. Chem. Soc. Rev. 51, 5498–5517 (2022).

    Article  CAS  PubMed  Google Scholar 

  3. Bondeson, D. P. et al. Cell Chem. Biol. 25, 78–87.e5 (2018).

    Article  CAS  PubMed  Google Scholar 

  4. Gadd, M. S. et al. Nat. Chem. Biol. 13, 514–521 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ward, J. A., Perez-Lopez, C. & Mayor-Ruiz, C. ChemBioChem 24, e202300163 (2023).

    Article  CAS  PubMed  Google Scholar 

  6. Li, W. et al. PLoS One 3, e1487 (2008).

    Article  ADS  MathSciNet  PubMed  PubMed Central  Google Scholar 

  7. Belcher, B. P., Ward, C. C. & Nomura, D. K. Biochem 62, 588–600 (2023).

    Article  CAS  Google Scholar 

  8. Kirsch, P., Hartman, A. M., Hirsch, A. K. H. & Empting, M. Molecules 24, 4309 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Gao, K., Oerlemans, R. & Groves, M. R. Biophys. Rev. 12, 85–104 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Lucas, X., Van Molle, I. & Ciulli, A. J. Med. Chem. 61, 7387–7393 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kori, S. et al. Bioorg. Med. Chem. 52, 116500 (2021).

    Article  CAS  PubMed  Google Scholar 

  12. Ishida, T. & Ciulli, A. SLAS Discov. 26, 484–502 (2021).

    Article  CAS  PubMed  Google Scholar 

  13. Schneider, H. et al. Preprint at bioRxiv https://doi.org/10.1101/2023.09.29.558399 (2023).

Download references

Acknowledgements

We thank the European Research Council (ERC) (ERC-2021-StG-101040046), ‘la Caixa’ Foundation, FERO-ASEICA, AECC, the Mark Foundation for Cancer Research, the Spanish Ministry of Science and Innovation (PID2020-120110RA-I00 and RYC2020-030061-I), and AGAUR-GenCat (2021SGR01279).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Cristina Mayor-Ruiz.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Whelan, R., Mayor-Ruiz, C. Chemical rewiring of ubiquitination by degraders and their selectivity routes. Nat Struct Mol Biol 31, 205–207 (2024). https://doi.org/10.1038/s41594-024-01215-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41594-024-01215-8

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research